Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28660324 | 0.85 | CYP2C19 (0.53) | CYP2C19HIF1AMAPTKMT2AKCNN4 | |
| SCHEMBL13865452 | 0.81 | KCNN4 (0.52) | CYP2C19HIF1AKCNN4ALDH1A1MIF | |
| SCHEMBL27708172 | 0.81 | CYP2C19 (0.49) | CYP2C19HIF1AMAPTKMT2AKCNN4 | |
| SCHEMBL17825682 | 0.80 | CYP2C19 (0.47) | CYP2C19HIF1AMAPTKMT2AKCNN4 | |
| SCHEMBL23094097 | 0.78 | MAPT (0.47) | CYP2C19HIF1AMAPTKMT2AKCNN4 | |
| SCHEMBL28454952 | 0.78 | ESR2 (0.49) | CYP2C19HIF1AALDH1A1MDM4MDM2 | |
| SCHEMBL5855770 | 0.78 | CYP2C19 (0.46) | CYP2C19HIF1AMAPTKMT2AKCNN4 | |
| SCHEMBL9502687 | 0.77 | KCNN4 (0.49) | CYP2C19HIF1AMAPTKMT2AKCNN4 | |
| SCHEMBL1926066 | 0.77 | CYP2C19 (0.45) | CYP2C19HIF1AMAPTKMT2AKCNN4 | |
| SCHEMBL27988566 | 0.77 | CYP2C19 (0.42) | CYP2C19HIF1AMAPTKMT2AKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0395219-B1 | Cephalosporins and their homologues, process for their preparation and pharmaceutical compositions | PFIZER (US) | 1998-09-30 | — | — | EP | claimed |
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| EP-2157429-A2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | Reverse Proteomics Research Institute Co., Ltd (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1553412-A1 | METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | CD2BP2, CD14, SPR | CYP2C19 4397/4885HIF1A 2663/4885MAPT 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.